Regeneron Pharmaceuticals - REGN Stock Forecast, Price & News

20 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last year. There are currently 1 sell rating, 6 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" REGN shares.
View REGN analyst ratings or view top-rated stocks.

20 analysts have issued 12 month target prices for Regeneron Pharmaceuticals' shares. Their REGN share price forecasts range from $575.00 to $925.00. On average, they anticipate the company's share price to reach $746.33 in the next year. This suggests a possible upside of 7.0% from the stock's current price.
View analysts price targets for REGN or view top-rated stocks among Wall Street analysts.

Regeneron Pharmaceuticals' stock was trading at $631.52 at the start of the year. Since then, REGN stock has increased by 10.4% and is now trading at $697.33.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our REGN earnings forecast.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced its quarterly earnings data on Wednesday, August, 3rd. The biopharmaceutical company reported $9.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $8.53 by $1.24. The biopharmaceutical company earned $2.86 billion during the quarter, compared to the consensus estimate of $2.80 billion. Regeneron Pharmaceuticals had a trailing twelve-month return on equity of 36.17% and a net margin of 39.97%. Regeneron Pharmaceuticals's quarterly revenue was down 44.4% compared to the same quarter last year. During the same period in the prior year, the company earned $27.97 earnings per share.
Read the conference call transcript.

423 employees have rated Regeneron Pharmaceuticals Chief Executive Officer Leonard S. Schleifer on Glassdoor.com. Leonard S. Schleifer has an approval rating of 87% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Walt Disney (DIS), Micron Technology (MU), Advanced Micro Devices (AMD) and Salesforce (CRM).

Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."

Regeneron Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include FMR LLC (9.34%), State Street Corp (4.71%), Dodge & Cox (2.09%), Loomis Sayles & Co. L P (1.63%), Price T Rowe Associates Inc. MD (1.55%) and Northern Trust Corp (1.10%). Insiders that own company stock include Andrew J Murphy, Arthur F Ryan, Arthur F Ryan, Bonnie L Bassler, Bonnie L Bassler, Christine A Poon, Christopher R Fenimore, George L Sing, George Yancopoulos, Huda Y Zoghbi, Joseph J Larosa, Joseph L Goldstein, Joseph L Goldstein, Leonard S Schleifer, Marc Tessier-Lavigne, Marion Mccourt, Michael S Brown, N Anthony Coles, Neil Stahl, P Roy Vagelos, Plew Daniel P Van, Plew Daniel P Van, Robert E Landry and Robert E Landry.
View institutional ownership trends.

Shares of REGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of REGN stock can currently be purchased for approximately $697.33.

Regeneron Pharmaceuticals (NASDAQ:REGN) has a market capitalization of $76.02 billion and generates $16.07 billion in revenue each year. The biopharmaceutical company earns $8.08 billion in net income (profit) each year or $50.10 on an earnings per share basis.

The company employs 10,368 workers across the globe.

Regeneron Pharmaceuticals' mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The official website for the company is www.regeneron.com. The biopharmaceutical company can be reached via phone at (914) 847-7000, via email at invest@regeneron.com, or via fax at 914-347-2113.